Hepatitis B virus infection in children

References

• Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 1965;191:541-6
   PubMed Web of Science ®Google Scholar
• Alter H. Baruch blumberg (1925-2011). Nature 2011;473(7346):155
   PubMed Web of Science ®Google Scholar
• Frost LJ, Reich MR. Access. How do good health technologies get topoor people in poor countires?. Harvard Center for Population and Development Studies, Cambridge, MA, USA; 2008. p. 68-90
   Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008;26(49):6266-73
   PubMed Web of Science ®Google Scholar
• WHO. Media centre, hepatitis B. 2014. Available from: www.who.int/mediacentre/factsheets/fs204/en/ [Last accessed on 19 November 2014]
   Google Scholar
• Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hpatol Int 2012;6:531-61
   PubMed Web of Science ®Google Scholar
• Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009;83(20):10538-47
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373(9663):582-92
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48(2):335-52
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011;55(1):183-91
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-85
   PubMed Web of Science ®Google Scholar
• Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133(5):1452-7
   PubMed Web of Science ®Google Scholar
• WHO. Global alert and response, hepatitis. B. Available from: www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index5.html [Last accessed on 19 November 2014]
   Google Scholar
• WHO. Immunization, vaccines and biologicals, hepatitis B. Available from: http://whqlibdoc.who.int/hq/2001/WHO_V&B_01.28.pdf?ua=1 [Last accessed on 19 November 2014]
   Google Scholar
• Ekra D, Herbinger KH, Konate S, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d’Ivoire. Vaccine 2008;26(22):2753-61
   PubMed Web of Science ®Google Scholar
• Rey-Cuille MA, Njouom R, Bekondi C, et al. Hepatitis B virus exposure during childhood in cameroon, central african republic and senegal after the integration of HBV vaccine in the expanded program on immunization. Pediatr Infect Dis J 2013;32(10):1110-15
   PubMed Web of Science ®Google Scholar
• Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine 2012;31(1):252-9
   PubMed Web of Science ®Google Scholar
• Howell J, Lemoine M, Thursz M. Prevention of materno-foetal transmission of hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges. J Viral Hepat 2014;21(6):381-96
   PubMed Web of Science ®Google Scholar
• Ashraf H, Alam NH, Rothermundt C, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010;10:208
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China–declining HBV prevalence due to Hepatitis B vaccination. Vaccine 2013;31(Suppl 9):J21-8
   PubMed Web of Science ®Google Scholar
• Utsumi T, Yano Y, Lusida MI, et al. Serologic and molecular characteristics of hepatitis B virus among school children in East Java, Indonesia. Am J Trop Med Hyg 2010;83(1):189-93
   PubMed Web of Science ®Google Scholar
• Koyama T, Matsuda I, Sato S, Yoshizawa H. Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981-1992) and epidemiological evidence for its efficacy. Hepatol Res 2003;26(4):287-92
   PubMed Web of Science ®Google Scholar
• Yeo Y, Gwack J, Kang S, et al. Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac J Cancer Prev 2013;14(11):6227-31
   PubMedGoogle Scholar
• Xeuatvongsa A, Komada K, Kitamura T, et al. Chronic hepatitis B prevalence among children and mothers: results from a nationwide, population-based survey in Lao People’s Democratic Republic. PLoS One 2014;9(2):e88829
   PubMed Web of Science ®Google Scholar
• Davaalkham D, Ojima T, Nymadawa P, et al. Seroepidemiology of hepatitis B virus infection among children in Mongolia: results of a nationwide survey. Pediatr Int 2007;49(3):368-74
   PubMed Web of Science ®Google Scholar
• Upreti SR, Gurung S, Patel M, et al. Prevalence of chronic hepatitis B virus infection before and after implementation of a hepatitis B vaccination program among children in Nepal. Vaccine 2014;32(34):4304-9
   PubMed Web of Science ®Google Scholar
• Al Awaidy ST, Bawikar SP, Al Busaidy SS, et al. Progress toward elimination of hepatitis B virus transmission in Oman: impact of hepatitis B vaccination. Am J Trop Med Hyg 2013;89(4):811-15
   PubMed Web of Science ®Google Scholar
• Jafri W, Jafri N, Yakoob J, et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 2006;6:101
   PubMed Web of Science ®Google Scholar
• Bialek SR, Helgenberger L, Fischer GE, et al. Impact of routine hepatitis B immunization on the prevalence of chronic hepatitis B virus infection in the marshall islands and the federated States of micronesia. Pediatr Infect Dis J 2010;29(1):18-22
   PubMed Web of Science ®Google Scholar
• Ang LW, Tey SH, Cutter J, et al. Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010. J Med Virol 2013;85(4):583-8
   PubMed Web of Science ®Google Scholar
• Ayoola AE, Tobaigy MS, Gadour MO, et al. The decline of hepatitis B viral infection in south-western saudi arabia. Saudi Med J 2003;24(9):991-5
   PubMed Web of Science ®Google Scholar
• Chen CY, Hsu HY, Liu CC, et al. Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: a 3-year study of national surveillance of primary school students. Vaccine 2010;28(34):5605-8
   PubMed Web of Science ®Google Scholar
• Chongsrisawat V, Yoocharoen P, Theamboonlers A, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006;11(10):1496-502
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Vu MH, Nguyen VC, et al. A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine 2014;32(2):217-22
   PubMed Web of Science ®Google Scholar
• Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 2011;15(2):e78-121
   PubMed Web of Science ®Google Scholar
• Edstam JS, Dulmaa N, Nymadawa P, et al. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. Prev Med 2002;34(2):207-14
   PubMed Web of Science ®Google Scholar
• WHO. Global alert and response. Global policy report on the prevention and control of viral hepatitis in WHO member states. 2013. Available from: www.who.int/csr/disease/hepatitis/global_report/en/ [Last accessed on 20 November 2014]
   Google Scholar
• Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57(4):730-5
   PubMed Web of Science ®Google Scholar
• Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012;16(2):e82-8
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011;18(5):369-75
   PubMed Web of Science ®Google Scholar
• Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49(4):652-7
   PubMed Web of Science ®Google Scholar
• Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009;50(2):264-72
   PubMed Web of Science ®Google Scholar
• Shahmoradi S, Yahyapour Y, Mahmoodi M, et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 2012;57(3):515-21
   PubMed Web of Science ®Google Scholar
• Pande C, Sarin SK, Patra S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat 2013;20(11):801-10
   PubMed Web of Science ®Google Scholar
• Su H, Zhang Y, Xu D, et al. Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS One 2013;8(8):e70768
   PubMed Web of Science ®Google Scholar
• Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat 2014;21(3):153-62
   PubMed Web of Science ®Google Scholar
• Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007;37(s1):S9-S19
   PubMedGoogle Scholar
• Martinson FE, Weigle KA, Mushahwar IK, et al. Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian children. J Med Virol 1996;48(3):278-83
   PubMed Web of Science ®Google Scholar
• Menendez C, Sanchez-Tapias JM, Kahigwa E, et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999;58(3):215-20
   PubMed Web of Science ®Google Scholar
• Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003;101(6):2419-25
   PubMed Web of Science ®Google Scholar
• Reda AA, Arafa MA, Youssry AA, et al. Epidemiologic evaluation of the immunity against hepatitis B in Alexandria, Egypt. Eur J Epidemiol 2003;18(10):1007-11
   PubMed Web of Science ®Google Scholar
• Peto TJ, Mendy ME, Lowe Y, et al. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC Infect Dis 2014;14:7
   PubMed Web of Science ®Google Scholar
• Adoga MP, Gyar SD, Pechulano S, et al. Hepatitis B virus infections in apparently healthy urban Nigerians: data from pre-vaccination tests. J Infect Dev Ctries 2010;4(6):397-400
   PubMed Web of Science ®Google Scholar
• Simani OE, Leroux-Roels G, Francois G, et al. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009;27(1):146-51
   PubMed Web of Science ®Google Scholar
• Muro FJ, Fiorillo SP, Sakasaka P, et al. Seroprevalence of hepatitis B and C viruses among children in kilimanjaro region, tanzania. J Pediatric Infect Dis Soc 2013;2(4):320-6
   PubMedGoogle Scholar
• Ochola E, Ocama P, Orach CG, et al. High burden of hepatitis B infection in Northern Uganda: results of a population-based survey. BMC Public Health 2013;13:727
   PubMed Web of Science ®Google Scholar
• Françoisa G, Dochez C, Mphahlelec MJ, et al. Hepatitis B vaccination in Africa: mission accomplished? The Southern African Journal of Epidemiology and Infection 2008;23:24-8
   Google Scholar
• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212-19
   PubMed Web of Science ®Google Scholar
• Mihigo R, Nshimirimana D, Hall A, et al. Control of viral hepatitis infection in Africa: are we dreaming? Vaccine 2013;31(2):341-6
   PubMed Web of Science ®Google Scholar
• Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006;13(12):787-98
   PubMed Web of Science ®Google Scholar
• Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000;18(Suppl 1):S17-19
   PubMedGoogle Scholar
• Silveira TR, da Fonseca JC, Rivera L, et al. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica 1999;6(6):378-83
   PubMedGoogle Scholar
• Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011;154(5):319-28
   PubMed Web of Science ®Google Scholar
• Escobedo-Melendez G, Fierro NA, Roman S, et al. Prevalence of hepatitis A, B and C serological markers in children from western Mexico. Ann Hepatol 2012;11(2):194-201
   PubMed Web of Science ®Google Scholar
• Villar LM, Amado LA, de Almeida AJ, et al. Low prevalence of hepatitis B and C virus markers among children and adolescents. Biomed Res Int 2014;2014:324638
   PubMed Web of Science ®Google Scholar
• Cabezas-Sánchez C, Trujillo-Villarroel O, Zavaleta-Cortijo C, et al. Prevalencia de la infección por el virus de hepatitis B en niños menores de 5 años de comunidades indígenas de la Amazonía peruana posterior a intervenciones mediante inmunización. Rev Peru Med Exp Salud Publica 2014;31:204-10
   PubMedGoogle Scholar
• Roman S, Jose-Abrego A, Fierro NA, et al. Hepatitis B virus infection in Latin America: a genomic medicine approach. World J Gastroenterol 2014;20(23):7181-96
   PubMed Web of Science ®Google Scholar
• Escobedo-Melendez G, Panduro A, Fierro NA, Roman S. High prevalence of occult hepatitis B virus genotype H infection among children with clinical hepatitis in west Mexico. Mem Inst Oswaldo Cruz 2014;109(6):728-37
   PubMed Web of Science ®Google Scholar
• Pan Americam Health Organization. World hepatitis day. Hepatitis vaccination in latin america and the caribbean. 2012. Available from: www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=18239&Itemid= [Last accessed on 23 November 2014]
   Google Scholar
• Nardone A, Anastassopoulou CG, Theeten H, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 2009;137(7):961-9
   PubMed Web of Science ®Google Scholar
• Gjorup IE, Skinhoj P, Bottiger B, Plesner AM. Changing epidemiology of HBV infection in Danish children. J Infect 2003;47(3):231-5
   PubMed Web of Science ®Google Scholar
• Cai W, Poethko-Muller C, Hamouda O, Radun D. Hepatitis B virus infections among children and adolescents in Germany: migration background as a risk factor in a low seroprevalence population. Pediatr Infect Dis J 2011;30(1):19-24
   PubMed Web of Science ®Google Scholar
• Zacharakis G, Kotsiou S, Papoutselis M, et al. Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece. Euro Surveill 2009;14(32):pii: 19297
   Google Scholar
• Dominguez A, Bruguera M, Vidal J, et al. Changes in the seroepidemiology of hepatitis B infection in Catalonia 1989-1996. Vaccine 2000;18(22):2345-50
   PubMed Web of Science ®Google Scholar
• Toy M, Onder FO, Wormann T, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011;11:337
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29(2):184-90
   PubMed Web of Science ®Google Scholar
• Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002;186(3):295-301
   PubMed Web of Science ®Google Scholar
• Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004;89(5):F456-60
   PubMed Web of Science ®Google Scholar
• Wen WH, Chang MH, Hsu HY, et al. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004;144(3):397-9
   PubMed Web of Science ®Google Scholar
• Vo Thi Diem H, Bourgois A, Bontems P, et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005;40(2):141-5
   PubMed Web of Science ®Google Scholar
• Zacharakis G, Koskinas J, Kotsiou S, et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years’ follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007;44(1):84-91
   PubMed Web of Science ®Google Scholar
• Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45(8):943-9
   PubMed Web of Science ®Google Scholar
• Manzat Saplacan RM, Mircea PA, Valean SD, et al. The long-term evolution of chronic hepatitis B acquired in childhood. J Gastrointestin Liver Dis 2009;18(4):433-8
   PubMed Web of Science ®Google Scholar
• Popalis C, Yeung LT, Ling SC, et al. Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat 2013;20(4):e20-6
   PubMed Web of Science ®Google Scholar
• Komatsu H, Inui A, Sogo T, et al. Chronic Hepatitis B virus infection in children and adolescents in Japan. A single-center 30-year study J Pediatr Gastroenterol Nutr 2015;60(1):99-104
   PubMed Web of Science ®Google Scholar
• Kew MC, Hodkinson J, Paterson AC, Song E. Hepatitis-B virus infection in black children with hepatocellular carcinoma. J Med Virol 1982;9(3):201-7
   PubMed Web of Science ®Google Scholar
• Hsu HC, Wu MZ, Chang MH, et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5(3):260-7
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen DS, Hsu HC, et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64(11):2377-80
   PubMed Web of Science ®Google Scholar
• Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990;65(1):174-6
   PubMed Web of Science ®Google Scholar
• Tazawa Y, Nishinomiya F, Noguchi H, et al. Hepatocellular carcinoma in children with hepatitis B surface antigen. Tohoku J Exp Med 1992;167(1):47-55
   PubMed Web of Science ®Google Scholar
• Akinyinka OO, Falade AG, Ogunbiyi O, Johnson AO. Hepatocellular carcinoma in Nigerian children. Ann Trop Paediatr 2001;21(2):165-8
   PubMed Web of Science ®Google Scholar
• Moore SW, Millar AJ, Hadley GP, et al. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. Cancer 2004;101(3):642-9
   PubMed Web of Science ®Google Scholar
• Satapathy SK, Garg S, Chauhan R, et al. Profile of chronic hepatitis B virus in children in India: experience with 116 children. J Gastroenterol Hepatol 2006;21(7):1170-6
   PubMed Web of Science ®Google Scholar
• Zhang XF, Liu XM, Wei T, et al. Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents. Pediatr Surg Int 2013;29(8):763-70
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76
   PubMed Web of Science ®Google Scholar
• Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S206-214
   PubMedGoogle Scholar
• Magnussen A, Parsi MA. Aflatoxins, hepatocellular carcinoma and public health. World J Gastroenterol 2013;19(10):1508-12
   PubMed Web of Science ®Google Scholar
• Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis 2010;14(3):495-504
   PubMed Web of Science ®Google Scholar
• Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332(7537):328-36
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2(8359):1099-102
   PubMed Web of Science ®Google Scholar
• Bzowej NH. Hepatitis B therapy in pregnancy. Curr Hepat Rep 2010;9(4):197-204
   PubMedGoogle Scholar
• Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190(9):489-92
   PubMed Web of Science ®Google Scholar
• Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10(5):452-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Gui X, Wang B, et al. A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission. Eur J Pediatr 2014;173(9):1161-8
   PubMed Web of Science ®Google Scholar
• Zou H, Chen Y, Duan Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19(2):e18-25
   PubMed Web of Science ®Google Scholar
• Singh AE, Plitt SS, Osiowy C, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat 2011;18(7):468-73
   PubMed Web of Science ®Google Scholar
• Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59(1):24-30
   PubMed Web of Science ®Google Scholar
• Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16(2):94-103
   PubMed Web of Science ®Google Scholar
• Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19(48):9377-82
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61(3):502-7
   PubMed Web of Science ®Google Scholar
• Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55(6):1215-21
   PubMed Web of Science ®Google Scholar
• Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10(5):520-6
   PubMed Web of Science ®Google Scholar
• Yu MM, Jiang Q, Ji Y, et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. J Clin Virol 2014;61(1):55-60
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 2014;60(2):468-76
   PubMed Web of Science ®Google Scholar
• Li XM, Yang YB, Hou HY, et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003;9(7):1501-3
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10(4):294-7
   PubMed Web of Science ®Google Scholar
• van Nunen AB, de Man RA, Heijtink RA, et al. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000;32(6):1040-1
   PubMed Web of Science ®Google Scholar
• Han L, Zhang HW, Xie JX, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011;17(38):4321-33
   PubMed Web of Science ®Google Scholar
• Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014;60(2):448-51
   PubMed Web of Science ®Google Scholar
• Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis 2013;33(2):138-46
   PubMed Web of Science ®Google Scholar
• Kumar A. Hepatitis B virus infection and pregnancy: a practical approach. Indian J Gastroenterol 2012;31(2):43-54
   PubMedGoogle Scholar
• Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576-88
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136(2):486-95
   PubMed Web of Science ®Google Scholar
• Piratvisuth T. Optimal management of HBV infection during pregnancy. Liver Int 2013;33(Suppl 1):188-94
   PubMed Web of Science ®Google Scholar
• Dunkelberg JC, Berkley EM, Thiel KW, Leslie KK. Hepatitis B and C in pregnancy: a review and recommendations for care. J Perinatol 2014;34(12):882-91
   PubMed Web of Science ®Google Scholar
• Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol 2012;18(34):4677-83
   PubMed Web of Science ®Google Scholar
• Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013;59(4):814-29
   PubMed Web of Science ®Google Scholar
• Petersen J. HBV treatment and pregnancy. J Hepatol 2011;55(6):1171-3
   PubMed Web of Science ®Google Scholar
• Ayres A, Yuen L, Jackson KM, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2014;21(11):809-17
   PubMed Web of Science ®Google Scholar
• Rawal BK, Parida S, Watkins RP, et al. Symptomatic reactivation of hepatitis B in pregnancy. Lancet 1991;337(8737):364
   PubMed Web of Science ®Google Scholar
• ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15(1):37-41
   PubMed Web of Science ®Google Scholar
• Bzowej NH. Optimal management of the hepatitis b patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012;11(2):82-9
   PubMedGoogle Scholar
• Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther 2014;12(7):775-82
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-2
   PubMed Web of Science ®Google Scholar
• Shah U, Kelly D, Chang MH, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009;48(4):399-404
   PubMed Web of Science ®Google Scholar
• Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010;52(6):2192-205
   PubMedGoogle Scholar
• Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. J Hepatol 2012;57(4):885-96
   PubMed Web of Science ®Google Scholar
• Peters MG. Special populations with hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S146-55
   PubMed Web of Science ®Google Scholar
• Haber BA, Block JM, Jonas MM, et al. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009;124(5):e1007-13
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996;23(4):700-7
   PubMed Web of Science ®Google Scholar
• Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004;23(5):441-5
   PubMed Web of Science ®Google Scholar
• Roskams T, Baptista A, Bianchi L, et al. Histopathology of portal hypertension: a practical guideline. Histopathology 2003;42(1):2-13
   PubMed Web of Science ®Google Scholar
• Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34(5):1021-6
   PubMed Web of Science ®Google Scholar
• Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003;18(3):246-52
   PubMed Web of Science ®Google Scholar
• Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006;13(23):2839-55
   PubMed Web of Science ®Google Scholar
• Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2(8564):877-80
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13(6):1035-9
   PubMed Web of Science ®Google Scholar
• Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991;86(3):327-30
   PubMed Web of Science ®Google Scholar
• Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114(5):988-95
   PubMed Web of Science ®Google Scholar
• El Sherbini A, Omar A. Treatment of children with HBeAg-positive chronic hepatitis B: A systematic review and meta-analysis. Dig Liver Dis 2014;46(12):1103-10
   PubMedGoogle Scholar
• Bortolotti F, Jara P, Barbera C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46(5):715-18
   PubMed Web of Science ®Google Scholar
• Boxall EH, Sira J, Ballard AL, et al. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006;78(7):888-95
   PubMed Web of Science ®Google Scholar
• Hsu HY, Tsai HY, Wu TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008;28(9):1288-97
   PubMed Web of Science ®Google Scholar
• Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78(286):155-63
   PubMedGoogle Scholar
• Yeung LT, Roberts EA. Current issues in the management of paediatric viral hepatitis. Liver Int 2010;30(1):5-18
   PubMed Web of Science ®Google Scholar
• Source G Available from: www.gsksource.com/gskprm/htdocs/documents/EPIVIR-HBV-PI-PIL.PDF [Last accessed on 12 November 2014]
   Google Scholar
• Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346(22):1706-13
   PubMed Web of Science ®Google Scholar
• Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43(2):225-32
   PubMed Web of Science ®Google Scholar
• Dikici B, Ozgenc F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19(2):127-33
   PubMed Web of Science ®Google Scholar
• Saltik-Temizel IN, Kocak N, Demir H. Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005;39(1):68-70
   PubMed Web of Science ®Google Scholar
• Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther 2003;25(12):3084-99
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008;47(6):1863-71
   PubMed Web of Science ®Google Scholar
• Chu M, Cho SM, Choe BH, et al. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2012;55(6):648-52
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359(23):2442-55
   PubMed Web of Science ®Google Scholar
• Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15(13):1695-700
   PubMed Web of Science ®Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282(24):2305-12
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185-95
   PubMed Web of Science ®Google Scholar
• Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012;56(6):2018-26
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140(1):132-43
   PubMed Web of Science ®Google Scholar
• Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53(3):763-73
   PubMed Web of Science ®Google Scholar
• Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006;28(2):184-203
   PubMed Web of Science ®Google Scholar
• Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42(12):3200-8
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-10
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133(5):1437-44
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Available from: http://packageinserts.bms.com/pi/pi_baraclude.pdf [Last accessed on 12 November 2014]
   Google Scholar
• Pawlowska M, Halota W, Smukalska E, et al. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2012;31(4):571-4
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48(1):99-108
   PubMed Web of Science ®Google Scholar
• Zhao Z, Murphy TV, Jacques-Carroll L. Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA. Vaccine 2011;30(1):14-20
   PubMed Web of Science ®Google Scholar
• Soeung SC, Thiep C, Duncan R, et al. Using data to guide policy: next steps for preventing perinatal hepatitis B virus transmission in Cambodia. Vaccine 2012;31(1):149-53
   PubMed Web of Science ®Google Scholar
• Black AP, Nouanthong P, Nanthavong N, et al. Hepatitis B virus in the Lao People’s Democratic Republic: a cross sectional serosurvey in different cohorts. BMC Infect Dis 2014;14:457
   PubMed Web of Science ®Google Scholar
• Rey-Cuille MA, Seck A, Njouom R, et al. Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS One 2012;7(5):e38153
   PubMed Web of Science ®Google Scholar
• Healy SA, Gupta S, Melvin AJ. HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther 2013;11(3):251-63
   PubMed Web of Science ®Google Scholar
• Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011;31(6):755-61
   PubMedGoogle Scholar
• Thomas H. Treatment of chronic Hepatitis B in resource-constrained countries: an economic solution is required. J Viral Hepat 2013;20(Suppl 1):2
   PubMedGoogle Scholar
• Spada E, Tosti ME, Zuccaro O, et al. Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy. J Infect 2011;62(2):165-71
   PubMed Web of Science ®Google Scholar
• GAVI alliance. Investing in immunisation through the GAVI Alliance. The evidence base. Available from: www.gavialliance.org/library/publications/the-evidence-base/ [Last accessed on 28 November 2014]
   Google Scholar
• A study of pegasys (Peginterferon Alfa-2a) versus untreated control in Children With HBeAg Positive Chronic Hepatitis B. Available from: https://clinicaltrials.gov/ct2/show/NCT01519960
   Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10(4):298-305
   PubMed Web of Science ®Google Scholar
• Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44(4):541-8
   PubMed Web of Science ®Google Scholar
• Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opin Pharmacother 2010;11(6):889-903
   PubMed Web of Science ®Google Scholar